1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Park HJ, Ahn JY, Jung HY, Lim H, Lee JH,
Choi KS, do Kim H, Choi KD, Song HJ, Lee GH and Kim JH: Clinical
characteristics and outcomes for gastric cancer patients aged 18-30
years. Gastric Cancer. 17:649–660. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Nam DH, Lee YK, Park JC, Lee H, Shin SK,
Lee SK, Lee YC, Cheong JH, Hyung WJ, Noh SH and Kim CB: Prognostic
value of early postoperative tumor marker response in gastric
cancer. Ann Surg Oncol. 20:3905–3911. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Mohri Y, Tanaka K, Ohi M, Saigusa S,
Yasuda H, Toiyama Y, Araki T, Inoue Y and Kusunoki M:
Identification of prognostic factors and surgical indications for
metastatic gastric cancer. BMC Cancer. 14:4092014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kwon OK, Yu W and Chung H: Prognostic
value of postoperative CA19-9 normalization in patients with
advanced gastric cancer. Hepatogastroenterology. 60:240–243.
2013.PubMed/NCBI
|
6
|
Kim DH, Oh SJ, Oh CA, Choi MG, Noh JH,
Sohn TS, Bae JM and Kim S: The relationships between perioperative
CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients
after curative radical gastrectomy. J Surg Oncol. 104:585–591.
2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Jo JC, Ryu MH, Koo DH, Ryoo BY, Kim HJ,
Kim TW, Choi KD, Lee GH, Jung HY, Yook JH, et al: Serum CA 19-9 as
a prognostic factor in patients with metastatic gastric cancer.
Asia Pac J Clin Oncol. 9:324–330. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Choi AR, Park JC, Kim JH, Shin SK, Lee SK,
Lee YC and Chung JB: High level of preoperative carbohydrate
antigen 19-9 is a poor survival predictor in gastric cancer. World
J Gastroenterol. 19:5302–5308. 2013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Shimada H, Noie T, Ohashi M, Oba K and
Takahashi Y: Clinical significance of serum tumor markers for
gastric cancer, A systematic review of literature by the task force
of the Japanese gastric cancer association. Gastric Cancer.
17:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
He CZ, Zhang KH, Li Q, Liu XH, Hong Y and
Lv NH: Combined use of AFP, CEA, CA125 and CAl9-9 improves the
sensitivity for the diagnosis of gastric cancer. BMC Gastroenterol.
13:872013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lee JC, Lee SY, Kim CY and Yang DH:
Clinical utility of tumor marker cutoff ratio and a combination
scoring system of preoperative carcinoembryonic antigen,
carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in
gastric cancer. J Korean Surg Soc. 85:283–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Li F, Li S, Wei L, Liang X, Zhang H and
Liu J: The correlation between pre-operative serum tumor markers
and lymph node metastasis in gastric cancer patients undergoing
curative treatment. Biomarkers. 18:632–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Yang AP, Liu J, Lei HY, Zhang QW, Zhao L
and Yang GH: CA72-4 combined with CEA, CA125 and CAl9-9 improves
the sensitivity for the early diagnosis of gastric cancer. Clin
Chim Acta. 437:183–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Bagaria B, Sood S, Sharma R and Lalwani S:
Comparative study of CEA and CA19-9 in esophageal, gastric and
colon cancers individually and in combination (ROC curve analysis).
Cancer Biol Med. 10:148–157. 2013.PubMed/NCBI
|
15
|
Ychou M, Duffour J, Kramar A, Gourgou S
and Grenier J: Clinical significance and prognostic value of CA72-4
compared with CEA and CA19-9 in patients with gastric cancer. Dis
Markers. 16:105–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
16
|
Japanese Gastric Cancer Association:
Japanese classification of gastric carcinoma: 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Handbook. New York:
Springer. 2010.
|
18
|
Gold P and Freedman SO: Demonstration of
tumor-specific antigens in human colonic carcinomata by
immunological tolerance and absorption techniques. J Exp Med.
121:439–462. 1965. View Article : Google Scholar : PubMed/NCBI
|
19
|
Koprowski H, Steplewski Z, Mitchell K,
Herlyn M, Herlyn D and Fuhrer P: Colorectal carcinoma antigens
detected by hybridoma antibodies. Somatic Cell Genet. 5:957–971.
1979. View Article : Google Scholar : PubMed/NCBI
|
20
|
Colcher D, Hand PH, Nuti M and Schlom J: A
spectrum of monoclonal antibodies reactive with human mammary tumor
cells. Proc Natl Acad Sci USA. 78:3199–3203. 1981. View Article : Google Scholar : PubMed/NCBI
|
21
|
Huang ZB, Zhou X, Xu J, Du YP, Zhu W, Wang
J, Shu YQ and Liu P: Prognostic value of preoperative serum tumor
markers in gastric cancer. World J Clin Oncol. 5:170–176. 2014.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Mittal A, Gupta SP, Jha DK, Sathian B and
Poudel B: Impact of various tumor markers in prognosis of gastric
cancer. Histopathology. Asian Pac J Cancer Prev. 14:1965–1967.
2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Cidón EU and Bustamante R: Gastric cancer:
Tumor markers as predictive factors for preoperative staging. J
Gastrointest Cancer. 42:127–130. 2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Liu X, Cai H and Wang Y: Prognostic
significance of tumour markers in Chinese patients with gastric
cancer. ANZ J Surg. 84:448–453. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Ucar E, Semerci E, Ustun H, Yetim T,
Huzmeli C and Gullu M: Prognostic value of preoperative CEA, CA
19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther.
25:1075–1084. 2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Yajima H, Omura N, Matai K, Mitsumori N,
Yoshida K and Yanaga K: Clinicopathological features of
CA19-9-producing gastric cancer. Hepatogastroenterology.
61:221–225. 2014.PubMed/NCBI
|
27
|
Tian SB, Yu JC, Kang WM, Ma ZQ, Ye X, Cao
ZJ and Yan C: Combined detection of CEA, CA 19-9, CA 242 and CA 50
in the diagnosis and prognosis of resectable gastric cancer. Asian
Pac J Cancer Prev. 15:6295–6300. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Sisik A, Kaya M, Bas G, Basak F and
Alimoglu O: CEA and CA 19-9 are still valuable markers for the
prognosis of colorectal and gastric cancer patients. Asian Pac J
Cancer Prev. 14:4289–4294. 2013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Han ES, Lee HH, Lee JS, Song KY, Park CH
and Jeon HM: At which stage of gastric cancer progression do levels
of carcinoembryonic antigen and carbohydrate antigen 19-9 increase?
Application in advanced gastric cancer treatment. J Gastric Cancer.
14:123–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Chen XZ, Zhang WK, Yang K, Wang LL, Liu J,
Wang L, Hu JK, Zhang B, Chen ZX, Chen JP, et al: Correlation
between serum CA724 and gastric cancer: Multiple analyses based on
Chinese population. Mol Biol Rep. 39:9031–9039. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Emoto S, Ishigami H, Yamashita H,
Yamaguchi H, Kaisaki S and Kitayama J: Clinical significance of
CA125 and CA72-4 in gastric cancer with peritoneal dissemination.
Gastric Cancer. 15:154–161. 2012. View Article : Google Scholar : PubMed/NCBI
|